Recently, a British biopharmaceutical company Almac Discovery announced that it has been granted by the FDA the privilege of treating orphans suffering ovarian cancer with testing medicine ALM201. Almac Discovery is a British biopharmaceutic company, headquartered in Northern Ireland, focusing on discovery and identification of innovative therapy methods to cure cancer. In America, rare diseases refer to the disease types whose sufferers number less 200 thousand. The incentive measures on drug research and development of rare diseases include various clinical development measures, such as related tax credit in clinical trial expenditure, reduction of FDA user fees, FDA assistance in clinical trial designs, and 7 year monopoly on the market after drugs are approved.

ALM201 is a first-in-class type of remedial polypeptide, developed to simulate some properties of one kind of protein spontaneously produced in bodies. The development of it was initially based on professor Tracy Robson’s research, which shows that FKBPL is naturally secreted protein enabling to impact several important biological processes of tumor, including cancer stem cells and angiogenesis.

In the vitro and vivo researches, ALM201 manifests extremely powerful anti-angiogenic activity which restrains the removal, tubule formation and capillary formation; while in the model of mice transplanted tumor, ALM201 was proofed to be very effective in the condition of low dose and with no influence of cell proliferation.